Eveline Van KeymeulenPartner at Latham & Watkins LLP
Eveline Van Keymeulen is a partner in Latham & Watkins' Brussels and Paris offices and Global Vice Chair of Latham & Watkins' Healthcare & Life Sciences Practice.
She advises multinational companies and start-ups in the pharmaceutical, biotech, medical devices, cosmetics, and food and beverage sectors on a broad variety of complex European, domestic and cross-border regulatory matters, including clinical trials, product approvals, regulatory incentives, market access, promotion and advertising, post-market obligations, and general compliance matters.
In addition, Eveline has extensive experience advising on cannabis and hemp based product regulations. She successfully challenged the legality of French hemp regulations in the first landmark case related to cannabidiol (CBD) products before the Court of Justice of the European Union (Case C-663/18, Kanavape), for which she won the ‘Creating New Standards’ award at the Financial Times European Innovative Lawyer Awards 2022 as well as the ‘Impact Case of the Year’ award at LMG Life Sciences 2021 and 2022.
Eveline is ranked in Chambers for Life Sciences Regulatory (2020-2022), as a Legal 500 Rising Star / Next Generation Lawyer in Healthcare and Life Sciences (2018-2022), and as a National and Global Leader by Who's Who Legal Life Sciences (2016-2022). She was awarded the European "Advisory Lawyer of the Year" (2021) award by LMG Life Sciences 2021. Clients particularly value her "high level of energy," and appreciate her for being "extremely flexible and genuinely engaged" as well as having "a can-do attitude”, while others have even called her a "rock star". She is further recognized as one of the leading life sciences practitioners in France by Legal Media Group 2021, Best Lawyers 2021, and Euromoney’s Women in Business Law Expert Guide 2021.
Eveline has authored numerous articles and has been a featured speaker on EU regulatory matters at prominent conferences such as the Pharmaceutical Law Academy in Cambridge. She also serves on the editorial board of the European Pharmaceutical Law Review. In addition, Eveline has been quoted in BBC Business Daily, Bloomberg, The Times, Les Echos, and other leading international business journals on life sciences regulatory and policy matters.